可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Bennett BJ,Scatena M,Kirk EA,et al.Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice.Arterioscler Thromb Vasc Biol[J].2006,26(9):2117-2124.
[2]Schoppet M,Sattler AM,Schaefer JR,et al.Increased osteoprotegerin serum levels in men with coronary artery disease[J].J Clin Endocrinol Metab,2003,88(3):1024-1028.
[3]Omland T,Ueland T,Jansson AM,et al.Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes[J].J Am Coll Cardiol,2008,51(3):627-633.
[4]Günes Y,Erbas C,Kavlak E,et al.Value of brain natriuretic peptide after acute myocardial infarction[J].Anadolu Kardiyoloji Dergisi,2008, 8(3):182-187.
[5]Schoppet M,Preissner KT,Hofbauer LC,et al.RANK ligand and osteoprotegerin.Paracrine regulators of bone metabolism and vascular function[J].Arterioscler Thromb Vasc Biol,2002,22(4):549-553.
[6]Avignon A,Sultan A,Piot C,et al.Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients[J].Diabetes Care,2005,28(9):2176-2180.
[7]Wittrant Y,Couillaud S,Theoleyre S,et al.Differentially regulates proteasome expression in ostoclast cultures[J].Biochem Biophys Res Commun,2002,293(1):38-40.
[8]Shuichi J,Yuji I,Atsushi S,et al.Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease[J].Circulation, 2002,106(10):l192-l194.
[9]Crisafulli A,Micari A,Altavilla D,et al.Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction[J].Clin Science,2005,109(10):389-395.
[10]Jono S,Shioi A,Ikari Y,et al.Vascular calcification in chronic kidney disease(Rev)[J].J Bone Miner Metab,2006,24(2):176-181.
[11]Sadanandan S,Cannon CP,Chekuri K,et al.Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction[J].J Am Coll Cardiol,2004,44(3):564-568.
[12]PalazzuoliA,Ascione R,Gallotta M, et al.Osteoprotegerin and B-type natriuretic peptide in acute coronary syndromes with preserved systolic function:relationto coronary artery disease extension[J].Int J Cardiol,2009,137(3):295-298.
[13]Grabowski M,Filipiak KJ,Malek LA,et al.Admission B-type natriuretic peptide assessment improves early risks tratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty[J].Int J Cardiol, 2007,115(3):386-390.
[14]Bassan R,Tura BR,Maisel AS,et al.B-type natriuretic peptide:a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department[J].Coron Artery Dis,2009,20(2):143-149.